Surgery Significantly Improves Neurocognition, Sleep, and Blood Pressure in Primary Hyperparathyroidism: A 3-Year Prospective Follow-Up Study

Sara Storvall; Eeva M. Ryhänen; Ilkka Heiskanen; Harri Sintonen; Risto P. Roine; Camilla Schalin-Jäntti

doi:10.1055/s-0043-118347

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2017; 49(10): 772-777
DOI: 10.1055/s-0043-118347

Endocrine Care

Surgery Significantly Improves Neurocognition, Sleep, and Blood Pressure in Primary Hyperparathyroidism: A 3-Year Prospective Follow-Up Study

Sara Storvall

¹Endocrinology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

,

Eeva M. Ryhänen

¹Endocrinology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

,

Ilkka Heiskanen

¹Endocrinology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

,

Harri Sintonen

²Department of Public Health, University of Helsinki, Helsinki, Finland

,

Risto P. Roine

³Group Administration, Research and Development, University of Helsinki and Helsinki University Hospital, Helsinki, and University of Eastern Finland, Kuopio, Finland

,

Camilla Schalin-Jäntti

¹Endocrinology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

› Institutsangaben

Abstract

Surgery for primary hyperparathyroidism (PHPT) improves health-related quality of life (HRQoL), but it is unclear whether the effects are sustained after medium-term (>2 years) follow-up, and whether the results on some or all dimensions of HRQoL will reach that of the general population. We performed a follow-up of HRQoL on average 3.3 years after surgery for PHPT using the 15D in our patient cohort (n=124) and compared the results to those of an age- and gender-standardized general population (n=1099). We studied self-reported blood pressure and current medications; new comorbidities were retrieved from electronic patient records. A total of 104 (83%) patients [eight with serum calcium (1.34–1.46 mmol/l)] returned the questionnaires. After a follow-up of 3.3 years (range 23 to 55 months), systolic and diastolic blood pressure had decreased significantly compared to baseline (the situation before surgery, p<0.001). Thirty-four (33%) had acquired a new diagnosis (range 1–7), the most common being cardiovascular disease and cancer. Mean 15D score was significantly better compared to baseline (p<0.001), the dimensions of sleeping, mental function, discomfort and symptoms, and depression had further improved (p<0.01), and no longer differed from that of the general population. In PHPT, after >2 years follow-up, surgery improves blood pressure and restores neurocognitive function and sleep to the level of the general population. The improvements observed in overall HRQoL at one year after surgery are sustained, but overall HRQoL does not reach that of the general population.

Key words

primary hyperpaparathyroidism - surgery - health-related quality of life - hypertension - medication - neurocognitive function

Volltext

Referenzen

References
1 Palmér M, Jakobsson S, Akerström G. et al Prevalence of hypercalcaemia in a health survey: A 14-year follow-up study of serum calcium values. Eur J Clin Invest 1988; 18: 39-46
2 Abood A, Vestergaard P. Increasing incidence of primary hyperparathyroidism in Denmark. Dan Med J 2013; 60: A4567
3 Bilezikian JP, Cusano NE, Khan AA . et al Primary hyperparathyroidism. Nat Rev Dis Primers 2016; 2: 16033
4 Bilezikian JP, Brandi ML, Eastell R. et al Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3561-3569
5 Silverberg SJ, Clarke BL, Peacock M. et al Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3580-3594
6 Grant P, Velusamy A. What is the best way of assessing neurocognitive dysfunction in patients with primary hyperparathyroidism?. J Clin Endocrinol Metab 2014; 99: 49-55
7 Ryhänen EM, Heiskanen I, Sintonen H. et al Health-related quality of life is impaired in primary hyperparathyroidism and significantly improves after surgery: A prospective study using the 15D instrument. Endocr Connect 2015; 4: 179-186
8 Brito K, Edirimanne S, Eslick GD. The extent of improvement of health-related quality of life as assessed by the SF36 and Paseika scales after parathyroidectomy in patients with primary hyperparathyroidism – a systematic review and meta-analysis. Int J Surg 2015; 13: 245-249
9 Cheng SP, Lee JJ, Liu TP. et al Quality of Life after surgery or surveillance for asymptomatic primary hyperparathyroidism: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2015; 94: e931
10 Koskinen S, Lundqvist A, Ristiluoma N. (eds) Health, functional capacity and welfare in Finland in 2011. Helsinki: National Institute for Health and Welfare (THL); 2012. Report 68/2012
11 Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999; 8: 45-54
12 Sintonen H. The 15D instrument of health-related quality of life: Properties and applications. Ann Med 2001; 33: 328-336
13 Hawthorne G, Richardson J, Day NA. A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med. 2001; 33: 358-370
14 Moock J, Kohlmann T. Comparing preference-based quality-of-life measures: Results from rehabilitation patients with musculoskeletal, cardiovascular, or psychosomatic disorders. Qual Life Res 2008; 17: 485-495
15 Richardson M, Campbell N, Allen L. et al The stroke impact scale: Performance as a quality of life measure in a community-based stroke rehabilitation setting. Disabil Rehabil 2016; 38: 1425-1430
16 Alanne S, Roine RP, Räsänen P. et al Estimating the minimum important change in the 15D scores. Qual Life Res 2015; 24: 599-606
17 Ishak WW, Bagot K, Thomas S. et al Quality of life in patients suffering from insomnia. Innov Clin Neurosci 2012; 9: 13-26
18 Ohayon MM. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med Rev 2002; 6: 97-111
19 Mittendorf EA, Wefel JS, Meyers CA. et al Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract 2007; 13: 338-344
20 Perrier ND, Coker LH, Rorie KD. et al Preliminary report: functional MRI of the brain may be the ideal tool for evaluating neuropsychologic and sleep complaints of patients with primary hyperparathyroidism. World J Surg 2006; 30: 686-696
21 Perrier ND, Balachandran D, Wefel JS. et al Surgery. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism. Surgery 2009; 146: 1116-1122
22 Murray SE, Pathak PR, Schaefer SC. et al Improvement of sleep disturbance and insomnia following parathyroidectomy for primary hyperparathyroidism. World J Surg 2014; 38: 542-548
23 Hedbäck G, Odén A. Increased risk of death from primary hyperparathyroidism–an update. Eur J Clin Invest 1998; 28: 271-276
24 Raue F. Increased incidence of cardiovascular diseases in primary hyperparathyroidism–a cause for more aggressive treatment?. Eur J Clin Invest 1998; 28: 277-278
25 Kalla A, Krishnamoorthy P, Gopalakrishnan A. et al Primary hyperparathyroidism predicts hypertension: Results from the National Inpatient Sample. Int J Cardiol 2017; 227: 335-337
26 Ryhänen EM, Leijon H, Metso S. et al A nationwide study on parathyroid carcinoma. Acta Oncol 2017; 56: 991-1003